3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
SANUWAVE Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -34.50%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for SANUWAVE Health's 3-Year ROIIC % or its related term are showing as below:
SNWV's 3-Year ROIIC % is ranked worse than 74.53% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs SNWV: -34.50
SANUWAVE Health (NAS:SNWV) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
SANUWAVE Health 3-Year ROIIC % Related Terms
SANUWAVE Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for SANUWAVE Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNWV vs RTGN, NNOX, LNSR: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, SANUWAVE Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SANUWAVE Health 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where SANUWAVE Health's 3-Year ROIIC % falls into.
SANUWAVE Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 4.909396 (Dec. 2025) - -8.952 (Dec. 2022) )
/
( 20.126 (Dec. 2025) - 60.301 (Dec. 2022) )
=
13.861396
/
-40.175
=
-34.50%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
SANUWAVE Health (SNWV) has a 3-Year ROIIC % of -34.50 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on SANUWAVE Health and its competitors. According to the industry distribution chart, SANUWAVE Health ranks #594 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is SANUWAVE Health's 3-Year ROIIC % too high?
SANUWAVE Health's current 3-Year ROIIC % is -34.50. Based on the distribution chart, SANUWAVE Health ranks #594 out of 797 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, SANUWAVE Health has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's 3-Year ROIIC % compare to RTGN and NNOX?
According to the Medical Devices & Instruments industry distribution chart, SANUWAVE Health ranks #594 out of 797 companies for 3-Year ROIIC %. This places SANUWAVE Health in the lower half of its industry. The industry median 3-Year ROIIC % is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on SANUWAVE Health and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SANUWAVE Health's current 3-Year ROIIC % is -34.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Fairly Valued. The stock's GF Value™ is $12.02, compared to a current price of $12.00 — trading 0.2% below its estimated fair value. The current 3-Year ROIIC % is -34.50. SANUWAVE Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current 3-Year ROIIC % is -34.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SANUWAVE Health (SNWV) Overvalued in 2026?
Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued.
The current stock price of $12.00 is trading 0.2% below its estimated GF Value™ of $12.02.
GuruFocus considers SANUWAVE Health to be Fairly Valued.
Key valuation signals for SNWV:
3-Year ROIIC %: -34.50
GF Value™: $12.02 vs. price of $12.00 (0.2% below fair value)
No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
38GF Score
Get the complete analysis for SNWV
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNWV has been successfully added to your 
